The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States
Abstract
Dengue is a global health problem requiring an effective, safe dengue vaccine.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 22, 2019
- Source ID
- 10.1093/infdis/jiz592
Entities
People
- Aaron Glass
- Brian Cuzzo
- Dongliang Wang
- Heather Friberg
- Jeffrey R. Currier
- Mark Abbott
- Mark Polhemus
- Matthew Bonaparte
- Michael F Princiotta
- Rafael De La Barra
- Richard G Jarman
- Saranya Sridhar
- Stephen J Thomas
- Tifany Machabert
- Timothy P Endy
Organizations
- Sanofi Pasteur
- State University of New York
- United States Army Medical Research and Development Command
- Walter Reed Army Institute of Research